A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet

Exclusion Criteria

• •History or clinical manifestations of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, endocrine, gastrointestinal, urological, neurological, or psychiatric disorders, or cancer
• •History of inflammatory arthritis
• •History of symptomatic hypotension
• •History of severe physical injury, direct impact trauma, or neurological trauma within 6 months prior to study start
• •History of seizure disorders
• •History of bipolar or major depressive disorder
• •History of stomach or intestinal surgery or resection that could potentially alter absorption and/or excretion of orally administered drugs with the exception of appendectomy, hernia repair, and cholecystectomy, which are allowed
• •History or presence of an abnormal ECG
• •History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias
• •Abnormality on the chest x-ray at Screening
• •History of alcoholism, drug abuse, or drug addiction
• •Used any nicotine-containing or nicotine-replacement products within 6 months prior to study start
• •Participated in any other investigational drug study in which receipt of an investigational study drug occurred within 1 month or 5 half-lives prior to study start
• •Used any prescription medications/products including monoamine oxidase inhibitors, thioridazine, pimozide, or antidepressants within 1 month (2 weeks for antibiotics) prior to study start, with the exception of hormone-replacement therapy or 2 weeks' use of narcotics for pain
• •Received any vaccination or immunization within 1 month prior to study start
• •Used PPIs or histamine H2-receptor antagonists within 1 month prior to study start
• •Hypersensitivity to rabeprazole, or any of its components, or to derived products of benzimidazoles (for Part 3 only)
• •Poor peripheral venous access
• •Received blood products within 2 months prior to study start
• •Positive urine drug or alcohol screen
• •Positive screen for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus types 1 and 2
• •Unable to consume a high-fat meal (for Parts 2 and 3 only)
• •Acute or chronic condition that would limit the subject's ability to complete or participate in this clinical study